$Viracta Therapeutics(VIRX.US)$Viracta Therapeutics Announces Positive Topline Nana-Val Results From Stage 1 of the Naval-1 Trial in Patients With Relapsed or Refractory Epstein-Barr Virus-Positive (Ebv+) Peripheral T-Cell Lymphoma
$Viracta Therapeutics(VIRX.US)$Moomoo 24/7· 1 min ago Viracta Therapeutics Says FDA Granted Orphan Drug Designation To Nana-val For Treatment Of Nasopharyngeal Carcinoma
$Viracta Therapeutics(VIRX.US)$RBC Capital Sticks to Their Buy Rating for Viracta Therapeutics (VIRX) RBC Capital analystGregory Renzamaintained a Buy rating on Viracta Therapeutics (VIRX–Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $1.41. According toTipRanks, Renza is a 4-star analyst with an average return of 8.7% and a 43.93% success rate. Renza covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, ACADIA...
$Viracta Therapeutics(VIRX.US)$SAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that additional data from the Phase 1b/2 clinical trial of Nana-val (nanatinostat in combination with valganciclovir) in patients with recurrent or metastatic (R/M) Epstein-Barr virus-positive (EBV+) nasopharyngeal carcino...
Viracta Therapeutics股票討論區
here are 6 cancer readouts to watch this quarter:
$ImmunityBio(IBRX.US)$ : Anktiva ▻ PDUFA ▻ Bladder CA
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib ▻ PDUFA ▻ Glioma
$GlycoMimetics(GLYC.US)$ : Uproleselan ▻ Ph3 ▻ AML
$FibroGen(FGEN.US)$ : Pamrevlumab ▻ Ph3 ▻ Pancreatic CA
$Viracta Therapeutics(VIRX.US)$ : Nana-val ▻ Ph3 ▻ Lymphoma
$Intra-Cellular Therapies(ITCI.US)$ Phase 3
$CG Oncology(CGON.US)$ Phase 3
$和黃醫藥(HCM.US)$ Phase 3
$Viracta Therapeutics(VIRX.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$烏龍製藥(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Marinus Pharmaceuticals(MRNS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3...
Viracta Therapeutics Says FDA Granted Orphan Drug Designation To Nana-val For Treatment Of Nasopharyngeal Carcinoma
RBC Capital analyst Gregory Renzamaintained a Buy rating on Viracta Therapeutics (VIRX – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $1.41.
According to TipRanks, Renza is a 4-star analyst with an average return of 8.7% and a 43.93% success rate. Renza covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, ACADIA...
暫無評論